Calidi Biotherapeutics
La Jolla, United States · Biotechnology, Health Care, Therapeutics · 31 employees
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped tech
Funding history
- Funding Round — $6.9M — Aug 2025
- Funding Round — $5.5M — Jun 2024
- Series seed — $1.0M — Mar 2024
- Series pre-seed — $10K — Mar 2024
- Series pre-seed — $195K — Mar 2024
Recent signals
- Jan 28, 2026: SEC 8-K (2.02): On January 28, 2026, Calidi Biotherapeutics, Inc. issued a press release detailing corporate updates and preliminary, unaudited financial results for the fiscal year ended December 31, 2025. This release highlights key operational initiatives for fiscal year 2026, presenting updates that are crucial for stakeholders. The financial data is based on information available to management and remains subject to final closing procedures and potential adjustments pending the completion of the audit. The release reflects the company's ongoing efforts and strategic direction, providing transparency to investors concerning its financial health and operations.
- Oct 31, 2025: Calidi Biotherapeutics Enters Stock Repurchase and Material Purchase Agreements
- Oct 27, 2025: SEC 8-K (1.01): On October 27, 2025, Calidi Biotherapeutics, Inc. entered into a Stock Repurchase Agreement (SRA) and a Material Purchase Agreement (MPA) with its subsidiary, Nova Cell, Inc. Under the SRA, Calidi repurchased 22,500,000 shares of Nova Cell common stock, equivalent to 75% equity interest and full ownership for a purchase price of $6,000,000. The payment includes cancellation of an existing promissory note with net offsets totaling $50,000. This strategic transaction marks a significant restructuring of Calidi's ownership in Nova Cell, potentially enhancing operational focus and financial health.
- Aug 21, 2025: Raised $6.9M
- Apr 10, 2025: Calidi Biotherapeutics Appoints Guy Travis Clifton as Chief Medical Officer
- Mar 31, 2025: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
- Oct 23, 2024: Calidi Biotherapeutics Announces $2 Million Registered Direct Offering and Private Placement
- Jun 06, 2024: Raised $5.5M
See plans & pricing → Track Calidi Biotherapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.